Seres Therapeutics (MCRB) Upgraded to Buy by Zacks Investment Research

Zacks Investment Research upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a buy rating in a research report sent to investors on Thursday morning. The firm currently has $6.25 price target on the biotechnology company’s stock.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Other analysts have also issued research reports about the company. Cantor Fitzgerald restated an overweight rating on shares of Seres Therapeutics in a report on Friday, November 23rd. Chardan Capital assumed coverage on shares of Seres Therapeutics in a research note on Monday, October 22nd. They issued a buy rating and a $15.00 price target on the stock. BidaskClub raised shares of Seres Therapeutics from a sell rating to a hold rating in a research note on Saturday, November 10th. ValuEngine raised shares of Seres Therapeutics from a sell rating to a hold rating in a research note on Tuesday, October 2nd. Finally, Oppenheimer set a $16.00 price target on shares of Seres Therapeutics and gave the stock a buy rating in a research note on Friday, November 9th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Seres Therapeutics presently has an average rating of Hold and an average price target of $13.06.

Shares of MCRB traded up $0.17 during mid-day trading on Thursday, reaching $6.38. The company’s stock had a trading volume of 73,200 shares, compared to its average volume of 98,175. The firm has a market capitalization of $244.32 million, a P/E ratio of -2.89 and a beta of 1.44. Seres Therapeutics has a 1 year low of $4.42 and a 1 year high of $11.35.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.03. The company had revenue of $9.06 million during the quarter, compared to analyst estimates of $23.43 million. Seres Therapeutics had a negative return on equity of 1,584.66% and a negative net margin of 515.16%. On average, equities analysts expect that Seres Therapeutics will post -2.58 earnings per share for the current year.

In other Seres Therapeutics news, insider John G. Aunins sold 14,279 shares of the stock in a transaction on Monday, October 15th. The shares were sold at an average price of $5.94, for a total transaction of $84,817.26. Following the transaction, the insider now directly owns 103,811 shares of the company’s stock, valued at $616,637.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John G. Aunins sold 14,282 shares of the stock in a transaction on Monday, December 17th. The stock was sold at an average price of $6.39, for a total transaction of $91,261.98. Following the transaction, the insider now directly owns 75,250 shares in the company, valued at $480,847.50. The disclosure for this sale can be found here. Corporate insiders own 37.10% of the company’s stock.

A number of institutional investors have recently bought and sold shares of MCRB. ARK Investment Management LLC increased its position in Seres Therapeutics by 23.7% during the third quarter. ARK Investment Management LLC now owns 4,040,735 shares of the biotechnology company’s stock worth $30,669,000 after buying an additional 774,307 shares during the last quarter. BlackRock Inc. increased its position in Seres Therapeutics by 23.0% during the second quarter. BlackRock Inc. now owns 2,240,844 shares of the biotechnology company’s stock worth $19,272,000 after buying an additional 418,589 shares during the last quarter. Millennium Management LLC increased its position in Seres Therapeutics by 100.6% during the second quarter. Millennium Management LLC now owns 172,173 shares of the biotechnology company’s stock worth $1,481,000 after buying an additional 86,348 shares during the last quarter. Schroder Investment Management Group increased its position in Seres Therapeutics by 104.9% during the second quarter. Schroder Investment Management Group now owns 135,166 shares of the biotechnology company’s stock worth $1,244,000 after buying an additional 69,205 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Seres Therapeutics by 6.4% during the third quarter. JPMorgan Chase & Co. now owns 421,494 shares of the biotechnology company’s stock worth $3,199,000 after buying an additional 25,287 shares during the last quarter. 78.35% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

See Also: Correction

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply